Literature DB >> 14973050

Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta.

Susanne Müerköster1, Kai Wegehenkel, Alexander Arlt, Maike Witt, Bence Sipos, Marie-Luise Kruse, Thorsten Sebens, Günter Klöppel, Holger Kalthoff, Ulrich R Fölsch, Heiner Schäfer.   

Abstract

Pancreatic ductal carcinoma is characterized by a profound chemoresistance. As we have shown previously, these tumor cells can develop chemoresistance by interleukin (IL)-1beta in an autocrine and nuclear factor-kappaB-dependent fashion. Because pancreatic ductal carcinoma contains many mesenchymal stromal cells, we further investigated how tumor-stroma interactions contribute to chemoresistance by using a transwell coculture model, including murine pancreatic fibroblasts and the chemosensitive human pancreatic carcinoma cell lines T3M4 and PT45-P1. If cultured with fibroblast-conditioned medium or kept in coculture with fibroblasts, both cell lines became much less sensitive toward treatment with etoposide than cells cultured under standard conditions. Furthermore, the secretion of IL-1beta in T3M4 and PT45-P1 cells was increased by the fibroblasts, and IL-1beta-receptor blockade abolished the resistance-inducing effect during cocultivation. This stimulated IL-1beta secretion could be attributed to nitric oxide (NO) released by the fibroblasts as an IL-1beta-inducing factor. Although both tumor cells secreted only little NO, which was in line with undetectable inducible nitric oxide synthase (iNOS) expression, fibroblasts exhibited significant iNOS expression and NO secretion that could be further induced by the tumor cells. Incubation of T3M4 and PT45-P1 cells with the NO donor S-Nitroso-N-acetyl-D,L-penicillamine up-regulated IL-1beta secretion and conferred resistance toward etoposide-induced apoptosis. Conversely, the resistance-inducing effect of the fibroblasts was significantly abolished, when the specific iNOS inhibitor aminoguanidine was added during coculture. Immunohistochemistry on tissue sections from human pancreatic ductal carcinoma also revealed iNOS expression in stromal cells and IL-1beta expression in tumor cells, thus supporting the in vitro findings. These data clearly demonstrate that fibroblasts contribute to the development of chemoresistance in pancreatic carcinoma cells via increased secretion of NO, which in turn leads to an elevated release of IL-1beta by the tumor cells. These findings substantiate the implication of tumor-stromal interactions in the chemoresistance of pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973050     DOI: 10.1158/0008-5472.can-03-1860

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  90 in total

1.  Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues.

Authors:  Kun Yuan; Natalya Frolova; Yi Xie; Dezhi Wang; Leah Cook; Yeon-Jin Kwon; Adam D Steg; Rosa Serra; Andra R Frost
Journal:  J Histochem Cytochem       Date:  2010-06-07       Impact factor: 2.479

2.  Caspase-1 inhibitors from an extremophilic fungus that target specific leukemia cell lines.

Authors:  Andrea A Stierle; Donald B Stierle; Teri Girtsman
Journal:  J Nat Prod       Date:  2012-02-01       Impact factor: 4.050

3.  Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma.

Authors:  Pakkayanee Sudsarn; Thidarut Boonmars; Wipaporn Ruangjirachuporn; Nisana Namwat; Watcharin Loilome; Pranee Sriraj; Ratchadawan Aukkanimart; Wonkchalee Nadchanan; Songsri Jiraporn
Journal:  Pathol Oncol Res       Date:  2015-08-16       Impact factor: 3.201

4.  Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction.

Authors:  Hirohisa Tsukamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2007-06-21       Impact factor: 5.150

5.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

6.  KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.

Authors:  Faraz Bishehsari; Lijuan Zhang; Usman Barlass; Nailliw Z Preite; Sanja Turturro; Matthew S Najor; Brandon B Shetuni; Janet P Zayas; Mahboobeh Mahdavinia; Abde M Abukhdeir; Ali Keshavarzian
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

7.  The course of gastric cancer following surgery is associated with genetic variations of the interleukin-1 receptor antagonist and interleukin-1β.

Authors:  Anke H van der Ploeg; Oliver Kumpf; Evelyn Seelow; Luis C Berrocal Almanza; Peter M Schlag; Ralf R Schumann; Lutz Hamann
Journal:  Gastric Cancer       Date:  2014-02-21       Impact factor: 7.370

8.  Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results.

Authors:  Mirko D'Onofrio; Stefano Crosara; Riccardo De Robertis; Giovanni Butturini; Roberto Salvia; Salvatore Paiella; Claudio Bassi; Roberto Pozzi Mucelli
Journal:  Technol Cancer Res Treat       Date:  2016-05-18

Review 9.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.

Authors:  Annika Lehmann; Carsten Denkert; Jan Budczies; Ann-Christin Buckendahl; Silvia Darb-Esfahani; Aurelia Noske; Berit Maria Müller; Marcus Bahra; Peter Neuhaus; Manfred Dietel; Glen Kristiansen; Wilko Weichert
Journal:  BMC Cancer       Date:  2009-11-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.